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Is translational research enhanced by the proximity of research institutes to hospitals? For 
scientists at the UK’s National Institute of Medical Research, which is facing relocation 
from London’s outskirts to its center, the question is no longer academic.Is it essential for basic scientists and 
clinicians to work next door to each 
other to deliver the best results for 
human health? The short answer is 
yes, at least in the view of Britain’s 
Medical Research Council (MRC), the 
government agency that funds much 
of biomedical research in the UK. This 
month, the MRC is seeking approval 
from the UK Treasury to move its 
largest establishment, the interna-
tionally respected National Institute 
for Medical Research (NIMR), from 
suburban Mill Hill in north London to 
the city center, at a cost of more than 
£320 million (US $605 million). After a 
debate over the institute’s future that 
has lasted almost four years, a deci-
sion from the Treasury is expected 
very soon.
The NIMR has a proud history dat-
ing back to 1913. Discoveries by its 
researchers include the influenza 
virus, acetylcholine and the nature 
of neurotransmitters, interferon, 
the nature of immunological toler-
ance, and the sex-determining gene. 
Among its alumni, NIMR boasts five 
Nobel prize winners, including the 
immunologist Peter Medawar and 
A.J.P. Martin, who developed gas 
chromatography. The institute today, 
with a budget of £25 million (US 
$47 million) and more than 700 staff 
members, is recognized for its work 
on infection and immunity, develop-
mental biology and genetics, neu-
roscience, and structural biology. 
Its future is of interest to scientists 
outside the UK as well as nationally 
not only because of its stature but 
because the changes it faces typify 
much broader shifts in the way bio-
medical research is being funded 
worldwide.
For some, the proposed move is 
an exciting step. “The renewed NIMR 
will potentially be the most power-ful biomedical research environ-
ment in the UK,” claims the MRC. If 
approved by the Treasury, the pro-
posed new institute will not be wholly 
owned by the MRC but instead will 
be a partnership with University Col-
lege London (UCL). It will be sited 
next door to UCL and minutes from 
University College Hospital. As well 
as giving its biomedical research-
ers access to other basic scientists 
at UCL, the council’s key aim is to 
improve the two-way links between 
bench researchers and clinicians. 
Like other public funding bodies on 
both sides of the Atlantic, including 
the US National Institutes of Health 
(NIH), the MRC is keen to intensify its 
efforts in translational research.
But some NIMR researchers are 
concerned. They question the evi-
dence that physical proximity is nec-
essarily the best way for scientists 
to work together in the 21st century. 
They point out that the potential 
benefits of the move are uncertain, 
whereas its costs are real, both to 
the public purse and, in the medium 
term, to the ongoing research activi-
ties of NIMR. “You have an institute 
at Mill Hill that functions well and is 
renowned,” says Robin Lovell-Badge, 
head of developmental genetics at 
NIMR who, with Peter Goodfellow, 
discovered SRY, the sex-determining 
gene, in 1991. “I personally think it is 
fine for the MRC to build an institute 
to strengthen translational research 
in central London, but it would have 
been more imaginative to start a new 
one, instead of moving the NIMR.” 
Having just been awarded an NIH 
grant for $3 million to study treat-
ments for stroke, together with col-
leagues at London’s King’s College 
and two US institutes, Lovell-Badge 
points out that he is already doing 
translational research. “It just empha-Cell 127, Ocsises to me that we don’t need to be 
located next to anyone to work with 
them,” he says.
Some researchers fear that a move 
will also have a negative impact on 
the institute’s basic science. “What 
frightens me,” says Jonathan Stoye, 
head of NIMR’s division of virology, 
“is that there is a calculation that 
says you can improve translational 
research by moving us, but there 
is no hard evidence that you will 
improve outputs that way…. What you 
need to do is facilitate links between 
researchers and clinicians, not put 
buildings next to each other.”
Stoye points out that NIMR already 
works with a long list of other hospi-
tals in different locations. For exam-
ple, in a Lancet paper last month, 
NIMR scientists reported a new test 
for active tuberculosis infection that 
they had developed in collaboration 
with researchers at St. George’s Hos-
pital Medical School on the opposite 
side of London.
The tensions over the NIMR’s 
future reflect a growing debate over 
how best to support high-quality bio-
medical science. In the public sector, 
in Europe and the US alike, funding 
bodies are under political pressure 
to show that taxpayers’ money deliv-
ers results for people’s health. In the 
US, the NIH Roadmap for medical 
research, launched in 2003, reaf-
firmed the need for intensified trans-
lational efforts as part of its move to 
“re-engineer” clinical research. In 
Britain, the MRC has been pushing 
for scientists to work more closely 
with clinicians for years, but in 2003 it 
formally made translational research 
a priority in its strategic plan for the 
decade. “The government, through 
the research councils, needs to be 
keeping its customers happy,” says 
Richard Henderson, director of the tober 20, 2006 ©2006 Elsevier Inc. 235
MRC’s Laboratory of Molecular Biol-
ogy (LMB) in Cambridge.
Henderson has not failed to spot 
the contrast between the agenda of 
the publicly funded research agen-
cies and those of some private foun-
dations. The Howard Hughes Medical 
Institute has just invested half a bil-
lion dollars in a state-of-the-science 
campus, deliberately sited 30 miles 
from Washington DC in the Virginia 
countryside. Janelia Farm, due to 
open this month, has been designed 
to give high-calibre scientists the 
freedom to pursue long-range, high-
risk research questions “without dis-
traction.” Ironically, Janelia Farm’s 
head, Gerald Rubin, has said that he 
modeled elements of the new cam-
pus on the original LMB, where he 
did his PhD. Henderson argues that, 
because private foundations such as 
the Howard Hughes have fewer stake-
holders to answer to than the public-
sector funding bodies, they are free 
to fund visibly separate research ini-
tiatives that clearly demonstrate their 
investment rather than allowing their 
funds to get blurred with those from 
other sources. As another example 
of this separation, Henderson cites 
the Wellcome Trust’s Sanger Insti-
tute outside Cambridge, with almost 
2000 researchers and with 90% 
funding by the Trust.
The current status of the NIMR 
belies a long and fraught debate over 
its future. In 2003, the MRC reviewed 
its plans for capital investment over 
the next decade not only for NIMR 
but also for other major MRC insti-
tutes. The review gave the NIMR full 
marks for its research but concluded 
that its facilities would need to be 
modernized to keep competitive, and 
the case for keeping it on its present 
Mill Hill site was “not strong,” given 
the council’s broader push for bring-
ing stand-alone institutes closer to 
other research bases. The MRC then 
set up a task force to re-examine 
the options, although modernizing 
the existing Mill Hill institute was the 
one option not under consideration. 
Privately, some scientists suspected 
that the MRC had a hidden agenda to 
close Mill Hill, or that its plans were 
the result of empire-building by cli-236 Cell 127, October 20, 2006 ©2006 Elnicians keen to regain some of the 
status that clinical research has lost 
in recent decades. That suspicion is 
vigorously dismissed by Colin Blake-
more, the MRC’s Chief Executive. “If 
there is a hidden agenda then after 
three years at the MRC I am still una-
ware of where it is hidden,” he told 
Cell. “The only agenda is to achieve 
the best possible future for the insti-
tute and its research in a promising 
new era.”
Late in 2004, the MRC accepted 
the recommendations of the task 
force that the institute should move 
alongside a university and teaching 
hospital, with a renewed focus on 
“basic and translational research,” 
while remaining in London. This rec-
ommendation was made on the con-
dition that the new institute would 
ultimately be an improvement on the 
existing one. In 2005 the MRC agreed 
to a partnership with University Col-
lege London. Staff from the MRC, 
the NIMR, and UCL drew up a draft 
business plan for the new institute. 
The MRC estimated then that the 
new institute would cost about £320 
million. This would be funded partly 
by £100 million from the MRC, with 
a further £140 million from a sepa-
rate government pot administered 
by the Office of Science and Innova-
tion (OSI), called the Large Facilities 
Capital Fund. The balance would 
come mainly from UCL and the pro-
ceeds of selling the Mill Hill site. Ear-
lier this year, the MRC bought the site 
adjacent to UCL but could not press 
ahead with its plans without approval 
from OSI and the Treasury. As Cell 
went to press, the final version of the 
business plan was to be presented to 
the MRC Council and then, following 
the Council’s approval, will be sent 
straight to the Treasury. The MRC 
expects a response from the Treas-
ury before the end of the year.
Assuming the plan goes ahead, it 
will be at least 6 years before the new 
institute is ready. The design phase 
will take until 2009 and building is due 
to be completed by 2012. Because 
the future of NIMR has taken longer to 
decide than originally expected, the 
timing of the building phase may pose 
a headache for the MRC. Sceptics sevier Inc.point out that by the time the MRC 
calls the builders in, every builder in 
London will already be committed to 
construction of the infrastructure for 
the 2012 Olympics, so costs are likely 
to spiral upwards. Blakemore con-
firms that the estimated cost of the 
proposed institute has risen, but for 
“explicable” reasons.
NIMR researchers accept that the 
proposed central London institute 
could be adequate. However, they 
are worried about other options that 
the Treasury has required the MRC 
to explore in its business plan as a 
means to justify its preferred option 
for a new institute in central London. 
These include moving the institute 
out of south-east England, or leaving 
the NIMR without new investment in 
its current aging buildings—the “do-
nothing” option. Blakemore says that 
these are not serious options but 
simply exercises to explain MRC’s 
reasons for its preferred plan. With-
out investment, the current NIMR 
site has at most a life expectancy of 
20 years and the MRC Council has 
already concluded that the site has 
no long-term future, he says. “We 
know that the do-nothing option is 
literally not an option, and the Treas-
ury is unlikely to challenge that,” says 
Blakemore. Likewise, he accepts that 
locating the institute outside south-
east England would effectively break 
up its existing teams. “One of our 
aims is to keep the excellent scien-
tists at NIMR working together.”
Even if the Treasury approves the 
preferred option, there are many 
important details that have yet to 
be resolved. “It is clearly very good 
that the MRC is thinking of invest-
ing £320 million in the institute and 
its continued success,” says Lovell-
Badge. “But we are very worried 
about the practicalities of the move, 
and whether the site is sufficient.” 
One obvious issue is size. The NIMR 
currently has a campus of more 
than 40 acres and includes sophis-
ticated animal research and con-
tainment laboratories. The new site 
covers less than one acre. Although 
the MRC has argued that it could fit 
most of the institute’s existing labo-
ratory space into a high-rise building 
on this site, it has not ruled out the 
possibility that some scientists could 
be based elsewhere.
A second issue is the animal facili-
ties. Some scientists understand 
that the animals could end up being 
sited 2 miles from the new building, 
while others fear that moving the ani-
mal facilities could lose vital research 
time. It could take 2 years or more 
after a move to re-establish specific 
lines of animals, forcing scientists 
either to wait or establish parallel 
animal facilities during the transi-
tion. There are also questions about 
whether the institute’s containment 
facilities for infectious agents can be 
moved to central London. “We wel-
come the investment in a new insti-
tute, but it is a major concern for me 
if we do not have those facilities on 
site,” says Stoye.
Yet more uncertainty surrounds 
the leadership of the institute. John 
Skehel, the director since 1987, 
retired last month. Although the MRC 
has tried to recruit a new director, it 
is unlikely to get one until the detailed 
future of the new institute is agreed. 
Although the MRC will not confirm 
any names, many scientists know 
that its preferred candidate is Scott 
Fraser, professor of bioengineering 
at Caltech in Pasadena, California. “I 
have always thought that NIMR is one 
of the real crown jewels,” says Fra-
ser, whose bioimaging skills and pre-
vious collaboration with NIMR teams have put him in the spotlight. He con-
firmed before Cell went to press that 
he was in “advanced discussions” 
with the MRC but stresses that there 
are still many undecided issues, as 
well as other opportunities for him 
to consider. Meanwhile, the MRC 
has asked 68-year-old Keith Peters, 
former head of the medical school at 
Cambridge University, to step in as 
interim caretaker. Until a permanent 
director is appointed, recruitment 
has been frozen and insiders report 
that some teams are now in need 
of new members, although, surpris-
ingly, given the continued uncer-
tainty, no senior scientists have yet 
left NIMR.
Many outside the NIMR hope that 
the years of argument over its future 
can be laid to rest. Richard Hender-
son, head of the MRC’s Laboratory 
of Molecular Biology, takes a philo-
sophical view. He acknowledges 
the fears of NIMR researchers but 
also understands the need for a 
government-funded enterprise to 
be accountable to its stakeholders 
and to serve its communities to the 
best standard possible. For that 
reason, he thinks it is “reasonable” 
that the MRC wants a new institute 
alongside a university and hospi-
tal. “The only question is this,” he 
says: “If you have got something 
that works, why change it?” The 
MRC could have developed its new 
institute with UCL while also main-Cell 127, Octaining the current site and NIMR 
infrastructure, he believes.
Clearly, the question of whether 
clinicians and basic scientists should 
rub shoulders daily is still unan-
swered. Advocates of the approach 
admit that there is no hard evidence 
to support the idea that sharing space 
results in better work, and they doubt 
it will ever be possible to document 
this in a systematic way. But they say 
they are persuaded of its benefits by 
their own working experience. “I do 
think in general there is an advan-
tage in proximity,” says Henderson. 
A similar view is held by Mark Wal-
port, director of the Wellcome Trust, 
and formerly chair of the division of 
medicine at Imperial College Lon-
don’s Hammersmith campus. “I think 
there are real advantages,” he says. 
He points to the successful links 
between groups of institutions else-
where. One example, he suggests, 
is Massachusetts General Hospital, 
MIT, and Harvard (although this net-
work has evolved rather than being 
deliberately created). And, Walport 
argues, since the MRC moved its 
Clinical Sciences Centre to the Ham-
mersmith Hospital, it has been work-
ing “incredibly well.” Of the proposed 
NIMR move he says: “Asked if this is 
a piece of cosmic irrationality—no, 
I don’t think so. We need as strong 
a biomedical science endeavour as 
possible, and we can never afford to 
stand still.”
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